Decitabine

2:38
MPN updates: personalized prognostication, novel treatments & more
Ruben Mesa
1:48
A new era for elderly AML patients
Farhad Ravandi
3:32
Venetoclax in AML updates: approval & combinations
Marina Konopleva
5:06
Personlized therapy for MDS: Advancements and the future
Torsten Haferlach
2:45
Identifying genetic mutations for diagnosing MDS
Torsten Haferlach
1:34
The importance of quickly spotting the signs of AML
Srdan Verstovsek
4:19
Intervening on time: how hypomethylating agents can prevent transition to AML
Srdan Verstovsek
3:05
Current research in elderly, untreated AML: venetoclax combinations
Marina Konopleva
2:57
Genetic biomarkers of response to venetoclax in AML
Marina Konopleva
3:20
Venetoclax combinations effective in elderly AML
Marina Konopleva
1:39
Current landscape and future directions for lower-risk MDS treatment
David Steensma
1:06
Is there hope for treating TP53-mutated MDS?
Mark Levis
1:12
Hypomethylating agents for low risk MDS
Eunice Wang
1:58
Maintenance therapy strategies to reduce relapse in AML
Charles Craddock
2:50
Epigenetic therapies in AML: current and future landscape
Andrew Wei
1:54
Promising results for venetoclax across multiple hematological malignancies
Giovanni Martinelli
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals